Biological analysis method based on post-incubation labeling
Through the biotin-(strepase) avidin coupling method labeled after incubation, the problem of solid particle markers affecting the incubation reaction is solved, the sensitivity and stability of biological analysis are improved, and multiple detection is simplified.
Patent Information
- Application Number
- CN202410157473.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-04
- Publication Date
- 2025-08-05
AI Technical Summary
In biological analysis, when solid particle markers are used, the incubation reaction is affected, resulting in a decrease in analysis performance, especially the sensitivity and reagent stability issues.
The post-incubation labeling method is used to bind the signal antibody to the streptavidin-coated solid particles after the incubation reaction to form an immune complex with a sandwich structure, avoiding covalent bonding before incubation.
Maintain the natural state of the incubation reaction, improve the sensitivity of the analysis and the stability of the reagent, simplify multiple detections, and reduce the complexity of the reagent system.
Smart Images

Figure CN120427893A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an improved bioanalytical method, particularly immunoassay and nucleic acid assay based on detecting signals from solid particles. Background Art
[0002] Bioanalytical methods based on the principle of biological affinity are widely used in fields such as scientific research, clinical diagnosis, drug development, and environmental and food monitoring. Depending on the nature of the test system (specimens or samples prepared from the human body, animal body, environment, food, or in scientific research) and the analyte (chemical substances, bioactive substances, genetic materials, microorganisms, biological tissues, etc.), there are many configurations of the detection system and modes of detection signals. However, the basic and common practice includes selecting one or more bioaffinity recognition partners (which can be chemical substances, bioactive substances, genetic materials, microorganisms, biological tissues, etc.) that can specifically bind to the analyte in the test system, and forming a detection system by the specific binding of the analyte and the recognition partner under artificially set environmental conditions (liquid phase, gas phase, or solid surface).
[0003] In various molecular diagnostic techniques applied to nucleic acid detection, the recognition partner is a nucleic acid that is complementary to the test nucleic acid sequence (partially or entirely), and in immunoassay, the recognition partners are antibodies for detecting antigens and antigens for detecting antibodies. High-sensitivity and high-specificity bioanalysis require that the recognition partner has a high binding ability and high selectivity for the analyte. If the binding ability is high, the amount or concentration of the analyte that can be detected is low; and if the selectivity is high, the possibility of interfering substances in the sample being misidentified as the analyte is low. Therefore, when developing a bioanalytical or detection method, selecting the recognition partner (such as an antibody) of the analyte is an important factor determining the analytical performance of the method.
[0004] After determining one or more recognition partners of the analyte, detection methods based on various signal modes can be established. The signal in the so-called "signal mode" can come from the label itself labeled on the recognition partner or the signal generated by the label participating in physical, chemical, or biochemical reactions in an artificially set environment. In some cases, the signal in the "signal mode" can also be the physicochemical signal change directly caused by the specific binding event of the analyte and the recognition partner. The former is called label-based bioaffinity analysis, and the latter is called label-free bioaffinity analysis. Figure 1 Here are some label-based and label-free detection methods commonly used in immunoassay.
[0005] Label-free bioaffinity analysis methods (such as various methods based on signal detection principles such as surface plasmon resonance, optical interference, and changes in the mass of the quartz crystal surface) are mainly used in the fields of life science research and drug development (studying the interaction between drug molecules and target proteins). The biological analysis carried out by aggregating a large number of antibodies and antigens to form large particles and causing changes in the light scattering effect can be regarded as an example of the application of label-free bioaffinity analysis methods in the field of clinical medicine( Figure 1 ).
[0006] However, in clinical immunoassay, the signals detected by the vast majority of methods come from the signals generated by the label or the physical, chemical, or biochemical reaction processes of the label participating in an artificially set environment. When the label is a radioactive isotope (such as in radioimmunoassay), a gold nanoparticle, or a magnetic particle (such as in lateral flow immunoassay), the detected signal (radioactivity intensity, color, or magnetic intensity) comes from the label itself. In the case where the label is a fluorescent or phosphorescent substance (such as quantum dots, rare earth long-lived phosphorescent molecules or microspheres, fluorescent molecules or microspheres, etc.), a chemiluminescent substance, an electrochemiluminescent substance, and an enzyme, the signal comes from the signal generated when the label undergoes a physical process (such as external light excitation), a chemical reaction process (such as chemiluminescence without the participation of an enzyme), an electrochemical reaction process (such as electrochemiluminescence), and a biochemical reaction process (chemiluminescence with the participation of an enzyme).
[0007] Figure 1 The analysis methods used in clinical medicine, life science research, and drug development have been well established in the past and have been applied to varying degrees in specific related fields. The focus of the present invention is not on the improvement of the recognition body of the analyte or its paired selection, nor on the improvement of the signal generation mechanism or signal detection principle in the detection method or principle.
[0008] Since labeling a chemical or biological molecule more or less changes the activity, affinity, solubility, and stability of this molecule, thereby affecting the bioaffinity reaction (i.e., the incubation reaction) and the finally manifested analytical performance indicators. When the label is not a small molecule but a macromolecule or a solid particle, the influence of the labeling method on the incubation reaction and analytical performance indicators is particularly serious. Maximally retaining the original state of the labeled molecule when introducing the label is conducive to the bioaffinity reaction occurring in a state closer to its natural state, thereby helping to improve the biological analysis performance (especially sensitivity, repeatability, and reagent stability). Since the solid particle label is an aggregate of labeled molecules, in some cases, the solid particle can improve the sensitivity of biological analysis, but the premise is that the introduction of the particle label has little influence on the incubation reaction. Regarding the application problem of particle labels in biological analysis, the present invention discloses a method for introducing solid particle labels after the incubation reaction.
[0009] Both immunoassay and nucleic acid analysis are bioanalytical methods based on the principle of biological affinity. For convenience, the following will take immunoassay as an example to elaborate on the invention content, but the essence of the method described in this invention is equally applicable to the analysis of nucleic acids as analytes. Summary of the Invention
[0010] Bioanalytical methods based on the antibody-antigen reaction are divided into homogeneous and heterogeneous immunoassays. Homogeneous immunoassay does not involve the participation of a solid surface, but involves labeling two recognition entities of the analyte with two labels respectively. Detection methods based on fluorescence resonance energy transfer ( resonance energy transfer, or fluorescence resonance energy transfer, FRET) and LOCI (luminescent oxygen channeling immunoassay) involving singlet oxygen (1ΔgO2) are both homogeneous detection methods. In the homogeneous detection based on FRET, the fluorescent label that receives the incident light is called the donor, and the other label that emits the detected light (fluorescence or phosphorescence) is called the acceptor; while in the homogeneous detection based on singlet oxygen (1ΔgO2), the label that receives the incident light is called the photosensitizer, and the other label that emits the detected fluorescence is called the emitter. Although having advantages in some applications, homogeneous immunoassay faces more interference factors and has a narrow dynamic range.
[0011] In the heterogeneous immunoassay system and procedure, there is a link involving the participation of a solid surface (bottom or inner wall of a well, inner wall of a reactor, surface of magnetic particles, etc.) in capturing the analyte or the complex formed by the analyte and the affinity recognition entity. This link has multiple functions such as capturing (the analyte), enrichment, and separation, reducing interference factors. This invention involves using a solid surface to capture the analyte or the complex containing the analyte, belonging to heterogeneous immunoassay.
[0012] The term "label" refers to any chemical or biochemical substance that, either by itself or through physical / chemical interaction with other reagents, generates a detectable signal (either a visible signal or a signal detectable by using a suitable instrument) that can be associated with the amount of the target analyte. Labels include, but are not limited to, molecules containing radioactive atoms (radioactivity), luminescent compounds (luminescing by photoexcitation or by a chemical reaction), electroactive compounds (generating an electrical signal through a redox reaction), magnetic particles (magnetic signal), enzymes (generating a detectable substance or an optical signal through reaction with a substrate), enzyme or enzymatic substrate (catalyzing a chemical / biochemical reaction). A label can consist of one or more signal-generating units and one or more reactive groups that readily form covalent bonds with the labeled chemical or biochemical molecule.
[0013] The "solid phase", also referred to as "solid support", is an insoluble, functionalized, polymeric or non-polymeric material to which compounds, biomolecules or reagents can be attached or covalently bound to be immobilized on the surface of the material and to facilitate their separation from excess reagents, excess reactants, soluble reaction by-products or solvents (by filtration, centrifugation, washing, etc.). The solid phases used in the methods described herein are widely described in the prior art (see, e.g., J.E. Butler, Methods, 2000, 22, 4-23). The term "solid phase" refers to a non-fluid substance, including: particles (including microparticles and beads) made of materials such as polymers, metals (paramagnetic, ferromagnetic particles), glass, and ceramics; gel materials such as silica, alumina, and polymer gels; capillaries that can be made of polymers, metals, glass and / or ceramics; zeolites and other porous materials; electrodes; microplates; solid strips; and cuvettes, test tubes, wafers or other sample containers of spectrometers. The solid-phase components in an analytical process are different from the inert solid surfaces that the analytical process may come into contact with in that the "solid phase" contains at least one functional structural component on its surface designed to interact with a capture antibody or a capture molecule. The solid phase can be a fixed component such as a test tube, a strip, a cuvette, a wafer, or a microplate, or a non-fixed component such as beads and microparticles.
[0014] Depending on the size of the analyte molecule and the antigen-antibody binding mode, immunoassays are further divided into sandwich assays and competitive assays. Similarly, for convenience, the following description of the invention will take the sandwich assay as an example, but the methods described are equally applicable to competitive immunoassays.
[0015] The solution involved in this invention is directed to immunoassay methods using solid particle markers. Similarly, for convenience, the description of the invention content will take luminescent particles and magnetic particle markers as examples, but the described method is also equally applicable to analysis methods using other signal modes or particle markers (such as nano-gold particles).
[0016] When the marker is a small molecule (molecular weight 10 2 ~10 3 D), since the molecular weight of an antibody is about 150 KD, the usual labeling ratio (1:4 - 10, that is, 4 - 10 labeling molecules are conjugated to one antibody) has little impact on the activity or solubility of the signal antibody, or the impact is within a controllable range. Therefore, when forming the {capture antibody / analyte / marked signal antibody} immune complex, the progress and result of the incubation reaction are less affected by the labeling molecules. However, when the marker is a solid particle at the nano or micro scale, the so-called labeling of an antibody with a marker actually means coating the solid particle with an antibody (see Figure 2 ). And the incubation reaction will partly or entirely change from a solid-liquid reaction to a solid-solid reaction, that is, the reaction between the solid particle coated with an antibody and the solid phase surface in the heterogeneous immunoassay system (see Figure 3 ). And when the solid phase is also a solid particle, since both the solid phase surface and the particle marker surface contain multiple antibody molecules, the incubation reaction will proceed in a cross-linked manner, resulting in flocculation of the solid particles coated with the capture antibody that were originally suspended and the marker particles coated with the signal antibody.
[0017] To keep the incubation reaction in the solid-liquid reaction state of small molecule labeling, this invention abandons the traditional practice of labeling antibodies with solid particles before the incubation reaction, and makes the particle labeling process a step after the incubation reaction, that is, the so-called post-incubation labeling. Further, this invention uses the biotin-(strept)avidin coupling method to achieve post-incubation labeling.
[0018] Biotin is a water-soluble vitamin (B7 or H) naturally present in some foods. It participates in multiple metabolic processes in the human body. Its extremely strong non-covalent interaction with avidin or streptavidin has long been used in the analysis, separation, and purification of bioactive substances (such as small molecule hormones, etc., and large molecule nucleic acids, proteins, etc.). The small molecular weight of biotin (244.31 D) and the rapid formation and high stability of the biotin-(strept)avidin complex in different solvents (the dissociation constant Kd for the biotin-avidin complex is about 10 -14 , and for the biotin-streptavidin is about 10 -15)The biotin-(strept)avidin chemistry has been widely used (E.P. Diamandis and T.K. Christopoulos, The biotin-(strept)avidin system: principles and applications in biotechnology, Clin. Chem. 1991, 37, 625-636). In these applications, since the valeric acid carboxyl group in the biotin molecule is reactive, it can be directly or indirectly (such as by conversion to an active ester) coupled with other biomolecules. When needed, the valeric acid carboxyl group in the biotin molecule can also be first linked with a linker or spacer that increases the spatial distance, so that in subsequent operations, the bicyclic heterocycle composed of an imidazolidinone ring and a tetrahydrothiophene ring in the biotin molecule can easily bind to avidin or streptavidin on the surface of a biomacromolecule (such as an antibody). The process of linking a biomacromolecule or other analyte to one or more imidazolidinone rings / tetrahydrothiophene rings in the biotin molecule through the valeric acid carboxyl group in the biotin molecule is called "biotinylation", and the antibody linked with the biotin molecule is called a biotinylated antibody. In competitive immunoassay, the analyte antigen or antigen derivative may be biotinylated.
[0019] In the prior art, the biotinylated antibody is usually a capture antibody, which is coupled with a streptavidin-coated solid phase (such as paramagnetic particles) to form a reagent component for specifically capturing the analyte. In the present invention, it is not the capture antibody that is biotinylated, but the signal antibody. The bicyclic heterocycle (imidazolidinone ring and tetrahydrothiophene ring) on the biotin molecule coupled with the signal antibody is not a signal group in any sense, but is used as a non-covalent linking group for post-incubation labeling. Different from any prior art, post-incubation labeling does not use a covalent bond (such as an amide bond) to link the label and the antibody, but is based on the strong affinity of biotin-streptavidin, so that the biotinylated antibody and the streptavidin-coated particle label can quickly bind in an aqueous solution ( Figure 4 ).
[0020] In one class of embodiments of the present invention, the particle label is a luminescent particle, such as a quantum dot or a fluorescent microsphere containing a long afterglow phosphorescent rare earth chelate. Through covalent crosslinking or adsorption, the surfaces of these luminescent particles are coated with streptavidin, and they are used alone as a class of reagents in immunoassays and are not used to label signal antibodies before the incubation reaction. After the immunoincubation reaction, an immune complex in a sandwich structure is formed on the solid phase surface. The solid phase surface is exposed to a suspension of streptavidin-coated luminescent particles, and the biotin heterocycle on the signal antibody binds to the streptavidin on the luminescent particles through non-covalent bonds. After separating and washing away the excess free luminescent particles, by exciting the luminescent particles with excitation light and detecting fluorescence or phosphorescence, a relationship between the fluorescence or phosphorescence intensity and the amount of the analyte can be established. Quantitative analysis of the analyte can also be completed through image analysis after imaging the luminescent particles anchored on the solid phase surface.
[0021] In another class of embodiments of the present invention, the particle label is a magnetic particle, such as a particle made of a single paramagnetic or ferromagnetic material or a composite material formed by it and other materials such as polymers or glass. Through covalent crosslinking or adsorption, the surfaces of these magnetic particles are coated with streptavidin, and they are used alone as a class of reagents in immunoassays and are not used to label signal antibodies before the incubation reaction. After the immunoincubation reaction, an immune complex in a sandwich structure is formed on the solid phase surface. The solid phase surface is exposed to a suspension of streptavidin-coated magnetic particles, and the biotin heterocycle on the signal antibody binds to the streptavidin on the magnetic particles through non-covalent bonds. After separating and washing away the excess free magnetic particles, the magnetic particles anchored by the biotin on the signal antibody can be individually detected or detected as a whole by a magnetic sensor, thereby establishing a relationship with the amount of the analyte.
[0022] In yet another class of embodiments of the present invention, the particle label is an opaque or colored particle, such as a nano-gold particle, a graphite particle, a metal oxide particle, or a particle made of a single material or a composite material containing a dye or a pigment. Through covalent crosslinking or adsorption, the surfaces of these colored particles are coated with streptavidin, and they are used alone as a class of reagents in immunoassays and are not used to label signal antibodies before the incubation reaction. After the immunoincubation reaction, an immune complex in a sandwich structure is formed on the solid phase surface. The solid phase surface is exposed to a suspension of streptavidin-coated colored particles, and the biotin heterocycle on the signal antibody binds to the streptavidin on the colored particles through non-covalent bonds. After separating and washing away the excess free colored particles, quantitative analysis of the analyte can be established through image analysis after imaging the colored particles anchored on the solid phase surface.
[0023] Except for the differences in the physicochemical properties of the marker particles or the solid state formed by aggregation, as well as the corresponding detection signal patterns and methods, the ways and steps of introducing the signal-generating substance (i.e., particle marker) in these embodiments are the same, and the coupling method of the marker particles with the signal antibody (biotin-streptavidin coupling) is also the same.
[0024] In summary, the following main steps and descriptions embody the essence of the present invention.
[0025] a. Contact a sample (liquid phase, solid phase or gas phase), which may contain the analyte and may or may not be pretreated, with a solid surface coated or anchored with an analyte recognition body (A) to form the following structure:
[0026] Solid surface—{Recognition body (A) / Analyte}
[0027] b. Contact another biotinylated recognition body (B) of the analyte with the above solid surface to form the following structure:
[0028] Solid surface—{Recognition body (A) / Analyte / Biotinylated recognition body (B)}
[0029] c. Contact streptavidin-coated solid particle markers with the above solid surface:
[0030] d. Separate the excess solid particle markers from the above solid surface to form the following structure:
[0031] Solid surface—{Recognition body (A) / Analyte / Biotinylated recognition body (B) / Marker};
[0032] e. Detect the physical or chemical signal of the solid particle markers bound to the above solid surface or the signal generated by their physical, chemical or biochemical reactions with other substances;
[0033] f. Obtain qualitative or quantitative information on whether the analyte exists or how much analyte exists in the sample through numerical processing of the above signals or analysis and processing of the formed images.
[0034] The solid phase described in the present invention includes, but is not limited to, various solid particles, containers, plates, fiber fabrics, optical fibers and other materials or implements made of single or composite materials; the solid surface is the surface or end face of these materials or implements; the solid surface containing the analyte recognition body (A) is such that the analyte recognition body (A) is immobilized or anchored on the solid surface through covalent bonds, adsorption, or ligand-receptor interactions;
[0035] [[ID=…]] The analyte recognition body is an antibody or a structural fragment of an antibody, nucleic acid or nucleic acid aptamer;
[0036] The described solid particle marker is composed of a single substance or a composite substance, including gold nanoparticles, graphite particles, magnetic (ferromagnetic or paramagnetic) substance particles, composite particles of magnetic (ferromagnetic or paramagnetic) substances and polymers or glass, quantum dots, luminescent microspheres formed by the composite of fluorescent and phosphorescent substances and a matrix, etc.);
[0037] The physical or chemical signals generated upon contact or the signals generated by their reaction with other substances through physical, chemical or biochemical reactions are optical signals (luminescence or reflected light), magnetic signals or electrical signals (current, voltage, impedance, complex impedance, frequency).
[0038] The present invention is not only different from the prior art in terms of the sequence of labeling, but also different from the covalent coupling method used in the prior art in the coupling method of labeling (non-covalent coupling).
[0039] Those skilled in the art understand that additional washing and / or separation steps may be included between the steps from a to e above. These steps are sometimes necessary and sometimes can be omitted. The addition, deletion or change of these steps does not change the essence of the present invention.
[0040] Based on the essence of the present invention reflected in the above embodiments, it can be found that post-incubation labeling has particular advantages for multiple detections. When using a planar solid-phase surface to anchor and capture antibodies, capture antibodies against different analytes can be anchored in different regions of the solid-phase surface ( Figure 5 ), so that multiple analytes can be detected simultaneously through a single incubation reaction. When small molecules are used to label antibodies, this multiple detection method is relatively easy to achieve. However, when solid particles are used as markers, multiple signal antibodies pre-labeled with solid particles will make the reagent system very complex and it is difficult to perform multiple analyses. Post-incubation labeling avoids these problems. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 is a conventional immunoassay method based on different detection signals.
[0042] Figure 2 is the case of small molecule-labeled (left) and solid particle-labeled (right) antibodies.
[0043] Figure 3 is the case of an immune sandwich complex formed on the solid-phase surface after small molecule-labeled (left) and solid particle-labeled (right) antibodies. Figure 4 The signal antibody is linked to the solid particle marker through non-covalent coupling of biotin-streptavidin.
[0044] Figure 5 Multiple analytes can be detected by anchoring antibodies against multiple analytes in different regions of the solid-phase surface.
Claims
1. A bioanalytical method using post-incubation labeling, the method comprising the following steps: a. A sample (liquid, solid, or gaseous phase) that may contain the analyte, whether pretreated or not, is brought into contact with a solid surface coated with or anchored with an analyte recognition body (A) to form the following structure: Solid surface—{identifier (A) / analyte} b. Allowing another biotinylated recognition body (B) of the analyte to contact the solid surface to form the following structure: Solid surface—{recognizer (A) / analyte / biotinylated recognizer (B)} c. Allow the streptavidin-coated solid particle marker to contact the solid surface: d. Separating the excess solid particle marker from the solid surface to form the following structure: Solid surface—{recognizer (A) / analyte / biotinylated recognition (B) / label}; e. detecting a physical or chemical signal of a solid particle marker bound to the solid surface or a signal generated by a physical, chemical or biochemical reaction thereof with other substances; f. obtaining qualitative or quantitative information on the presence or absence of the analyte in the sample or the amount of the analyte present by numerical processing of the above signal or analysis of the formed image; The steps from a to e may include additional washing and / or separation steps; The solid phase includes, but is not limited to, various single or composite solid particles, containers, flat plates, fiber fabrics, optical fibers, and other materials or objects; the solid phase surface is the surface or end face of these materials or objects; the solid phase surface containing the analyte recognition entity (A) is immobilized or anchored on the solid phase surface by covalent bonds, adsorption, or ligand-receptor interactions; The analyte recognition body is an antibody or a structural fragment of an antibody, a nucleic acid or a nucleic acid aptamer; The solid particle marker is composed of a single substance or a composite substance, including gold nanoparticles, graphite particles, magnetic (ferromagnetic or paramagnetic) material particles, composite particles of magnetic (ferromagnetic or paramagnetic) material and polymer or glass, quantum dots, luminescent microspheres composed of fluorescent phosphorescent material and matrix, etc.); The physical or chemical signal generated during the contact or the signal generated by physical, chemical or biochemical reaction with other substances is a light signal (luminous or reflected light), a magnetic signal or an electrical signal (current, voltage, impedance, complex impedance, frequency).
2. An immunoassay method using post-incubation labeled luminescent particles, the method comprising the following steps: a. Allow a sample, pretreated or unpretreated, that may contain the analyte to contact a solid surface coated or anchored with an antibody to the analyte (capture antibody) to form the following structure: Solid surface—{capture antibody / analyte} b. Allowing the biotinylated analyte signal antibody to contact the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody} c. allowing the streptavidin-coated solid luminescent particle marker to contact the solid surface; d. Separating the excess luminescent particle marker from the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody / luminescent particle} e. by exciting the luminescent particles bound to the solid surface and detecting the excitation light; f. obtaining qualitative or quantitative information on the presence or absence of the analyte in the sample or the amount of the analyte present by numerically processing the above signal or processing the formed image; The steps from a to e may include additional washing and / or separation steps; The solid phase includes, but is not limited to, various single or composite solid particles, containers, flat plates, fiber fabrics, optical fibers, and other materials or objects; the solid phase surface coated with the analyte antibody is the surface or end face of these materials or objects; the solid phase surface coated with the analyte antibody is the solid phase surface where the analyte antibody is fixed to the analyte antibody by covalent bonding, adsorption, or ligand-receptor interaction; The luminescent particles are single or composite material particles containing fluorescent or phosphorescent substances, and their diameters are between 1.0 nanometers and 5.0 micrometers.
3. An immunoassay method using post-incubation labeled magnetic particles, the method comprising the following steps: a. Allowing a pretreated or unpretreated sample that may contain the analyte to contact a solid surface coated with or anchored with an antibody to the analyte (capture antibody) to form the following structure: Solid surface—{capture antibody / analyte} b. Allowing the biotinylated analyte signal antibody to contact the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody} c. allowing the streptavidin-coated magnetic particle marker to contact the solid surface; d. Separating the excess magnetic particle marker from the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody / magnetic particles} e. Using a magnetic sensitive detection device to detect a single magnetic particle, a partial region or all of the magnetic particles on the solid surface; f. obtaining qualitative or quantitative information on the presence or absence of the analyte in the sample or the amount of the analyte present by numerically processing the above signal or processing the formed image; The steps from a to e may include additional washing and / or separation steps; The solid phase includes, but is not limited to, various single or composite solid particles, containers, flat plates, fiber fabrics, optical fibers, and other materials or objects; the solid phase surface coated with the analyte antibody is the surface or end face of these materials or objects; the solid phase surface coated with the analyte antibody is the solid phase surface where the analyte antibody is fixed to the analyte antibody by covalent bonding, adsorption, or ligand-receptor interaction; The magnetic particles are single or composite material particles containing ferromagnetic or paramagnetic substances, and their diameters are between 10 nanometers and 10 micrometers.
4. An immunoassay method using incubated colored particles, the method comprising the following steps: a. Allow a sample, pretreated or unpretreated, that may contain the analyte to contact a solid surface coated or anchored with an antibody to the analyte (capture antibody) to form the following structure: Solid surface—{capture antibody / analyte} b. Allowing the biotinylated analyte signal antibody to contact the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody} c. allowing the colored particle marker coated with streptavidin to contact the solid surface; d. Separating the excess colored particle marker from the solid surface to form the following structure: Solid surface—{capture antibody / analyte / biotinylated signal antibody / colored particles} e. obtaining an image of part or all of the colored particles on the solid surface by microscopic imaging; f. obtaining qualitative or quantitative information on the presence or absence of the analyte in the sample or the amount of the analyte present by counting the colored particles on the image or other image processing methods; The steps from a to e may include additional washing and / or separation steps; The solid phase includes, but is not limited to, various single or composite solid particles, containers, flat plates, fiber fabrics, optical fibers, and other materials or objects; the solid phase surface coated with the analyte antibody is the surface or end face of these materials or objects; the solid phase surface coated with the analyte antibody is the solid phase surface where the analyte antibody is fixed to the analyte antibody by covalent bonding, adsorption, or ligand-receptor interaction; The colored particles are nano-gold particles, graphite particles, metal oxide particles, and single material or composite material particles containing dyes and pigments, and their diameters are between 10 nanometers and 10 micrometers.
5. A multiplex detection bioanalysis method using post-incubation labeling, the method comprising the following steps: a. A sample (liquid, solid, or gaseous phase), pretreated or unpretreated, which may contain multiple analytes, is brought into contact with multiple analyte recognition bodies (A) coated or anchored on different regions of a solid surface, thereby forming multiple structures as follows on different regions of the solid surface: Solid surface—{identifier (A) / analyte} b. allowing another biotinylated recognition body (B) of a different analyte to contact the solid surface to form a plurality of the following structures in different regions of the solid surface: Solid surface—{recognizer (A) / analyte / biotinylated recognizer (B)} c. Allow the streptavidin-coated solid particle marker to contact the solid surface: d. Separating the excess solid particle marker from the solid surface to form a plurality of the following structures: Solid surface—{recognizer (A) / analyte / biotinylated recognition (B) / label}; e. detecting a physical or chemical signal of a solid particle marker bound to the solid surface or a signal generated by a physical, chemical or biochemical reaction thereof with other substances; f. obtaining qualitative or quantitative information on the presence or absence of certain analytes in the sample or the amount of certain analytes present by numerical processing of the above-mentioned signal or analysis of the formed image; The steps from a to e may include additional washing and / or separation steps; The solid phase includes, but is not limited to, various single or composite solid particles, containers, flat plates, fiber fabrics, optical fibers, and other materials or objects; the solid phase surface is the surface or end face of these materials or objects; the solid phase surface containing the analyte recognition entity (A) is immobilized or anchored on the solid phase surface by covalent bonds, adsorption, or ligand-receptor interactions; The analyte recognition body is an antibody or a structural fragment of an antibody, a nucleic acid or a nucleic acid aptamer; The solid particle marker is composed of a single substance or a composite substance, including gold nanoparticles, graphite particles, magnetic (ferromagnetic or paramagnetic) material particles, composite particles of magnetic (ferromagnetic or paramagnetic) material and polymer or glass, quantum dots, luminescent microspheres composed of fluorescent phosphorescent material and matrix, etc.); The physical or chemical signal generated during the contact or the signal generated by physical, chemical or biochemical reaction with other substances is a light signal (luminous or reflected light), a magnetic signal or an electrical signal (current, voltage, impedance, complex impedance, frequency).
